Revenue for the 12 months ended November 30 was €1.02bn which, even excluding the contribution made by the technical plastics unit Gerresheimer sold eighteen months ago, is 5.6 per cent up on fiscal 2009.
And, according to the German plastic and glass packaging specialist, 82 per cent of this revenue came from the drug industry, with insulin pens, inhalers, vials, ampoules and prefillable syringes being the top sellers.
This was reflected in the performance of Gerresheimer’s business segments, with sales from moulded and tubular glass climbing 6.3 per cent to €327.3m and 2.5 per cent to €310.4m, beating plastic systems into third place.
Gerresheimer’s moulded glass unit was also help by increased demand for cosmetic packaging, which the firm said had shown signs of revival in fiscal 2010 but did not give specific figures.
Revenue from the firm’s life sciences business, which makes glassware used for drug R&D and analytics, also increased in the 12-months to November 30, 2010, growing some 8.8 per cent to €95m.
The fiscal 2010 results are largely in keeping with predictions Gerresheimer issued in April last year when it forecast that sales to the pharmaceutical industry would continue to grow.
However, according to the firm, “[while] sales of primary packaging and drug delivery devices for the pharmaceutical industry were good…pharma customers maintained the significantly reduced inventory observed in [fiscal 2009] and did not rebuild stocks.”